Oncotelic Therapeutics, Inc. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
Oncotelic Therapeutics, Inc. (OTLC) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $12.84 thousand as of 2021-09-30, per its 10-Q filed 2021-11-22.
Discontinued › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2021-11-22
- 2021-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $12.84K.
- 2021-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $25.68K.
- 2021-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $38.52K.
- 2020-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $12.84K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2021-09-30 | $12.84K 10-Q · filed 2021-11-22 |
| 2021-06-30 | $25.68K 10-Q · filed 2021-08-20 |
| 2021-03-31 | $38.52K 10-Q · filed 2021-05-24 |
| 2020-09-30 | $12.84K 10-Q · filed 2020-11-16 |
| 2020-06-30 | $25.68K 10-Q · filed 2020-08-14 |
| 2020-03-31 | $38.52K 10-Q · filed 2020-06-29 |